Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team ...
An expert discusses the current understanding of corticosteroids in managing pulmonary fibrosis and how it has evolved in ...
Low total cholesterol levels were tied to an increased risk of death for pulmonary fibrosis patients with disease of unknown ...
Pulmonary fibrosis in patients with COVID-19 tends ... leading to increased risk of death in COVID-19. The study involved a suppressor cell called 7-Gene-M-MDSC – short for monocytic myeloid ...
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback